Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: Phase III KEYNOTE-676 study.

Authors

Ashish M. Kamat

The University of Texas MD Anderson Cancer Center, Houston, TX

Ashish M. Kamat , Neal D. Shore , Noah M. Hahn , Shaheen Riadh Alanee , Hiroyuki Nishiyama , Shahrokh F. Shariat , Kijoeng Nam , Ekta Kapadia , Tara L. Frenkl , Gary D. Steinberg

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin unresponsive high-risk non-muscle invasive bladder cancer: CREST Study Cohort B.

First Author: Neal D. Shore

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.

First Author: Girish S. Kulkarni

insert_chart_outlined

Poster

2021 Genitourinary Cancers Symposium

bookmark_border

Pembrolizumab for the treatment of patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin: Extended follow-up of KEYNOTE-057 cohort A.

First Author: Arjun Vasant Balar

insert_chart_outlined

Poster

2019 Genitourinary Cancers Symposium

bookmark_border

Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.

First Author: Ashish M. Kamat